DeepMed Research

Entinostat

Generic Name: Entinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀N_₄O_₃

CAS Number: 209783-80-2

Unique Ingredient Identifier: 1ZNY4FKK9H

Background: Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.

Indication: 联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。

Clinical Trials

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

Phase 1

Withdrawn

Conditions: Esophageal Neoplasms
Esophagus Neoplasm
Esophagus Cancer
Neoplasms
Neoplasms, Esophageal
Esophageal Cancer (EsC)

Interventions: Drug: Nivolumab
Drug: Entinostat
Biological: Montanide(R) ISA-51 VG Adjuvant
Biological: H1299 Cell Lysates

First Posted Date: 2023-06-12

Last Posted Date: 2024-08-05

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05898828

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

Phase 1

Recruiting

Conditions: Advanced Pancreatic Carcinoma
B-Cell Non-Hodgkin Lymphoma
Metastatic Pancreatic Carcinoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Lymphoma
Stage II Pancreatic Cancer AJCC v8
Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory T-Cell Non-Hodgkin Lymphoma
Refractory Pancreatic Carcinoma

Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694
Procedure: Core Biopsy
Drug: Entinostat

First Posted Date: 2021-09-23

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT05053971

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Phase 1

Active, not recruiting

Conditions: Oropharyngeal Cancer
Vaginal Cancer
Neck Cancer
Anal Cancer
Colon Cancer
Human Papillomavirus
Cervical Cancer
Vulvar Cancer
HPV
Penile Cancer

Interventions: Drug: Bintrafusp Alfa
Drug: PDS01ADC
Drug: Entinostat

First Posted Date: 2021-01-14

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04708470

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Phase 1

Completed

Conditions: Extensive Stage Lung Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Biological: Atezolizumab
Drug: Carboplatin
Drug: Entinostat
Drug: Etoposide

First Posted Date: 2020-11-17

Last Posted Date: 2023-10-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT04631029

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 2 locations

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Phase 1

Terminated

Conditions: Breast Cancer
Triple Negative Breast Cancer
HER2+ Breast Cancer
Hormone Receptor Negative Breast Cancer
Metastatic Breast Cancer

Interventions: Biological: Brachyury-TRICOM
Biological: M7824
Drug: Entinostat
Biological: Ado-trastuzumab emtansine

First Posted Date: 2020-03-05

Last Posted Date: 2022-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT04296942

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Pembrolizumab
Drug: Entinostat
Procedure: Procedure/Surgery

First Posted Date: 2019-06-07

Last Posted Date: 2025-03-18

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT03978624

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Phase 1

Withdrawn

Conditions: Advanced Lymphoma
Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma
Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma
Refractory Malignant Solid Neoplasm
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Refractory Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Stage II Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8

Interventions: Drug: Entinostat
Drug: Molibresib

First Posted Date: 2019-04-24

Last Posted Date: 2020-09-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03925428

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1

Terminated

Conditions: Ovarian Clear Cell Adenocarcinoma
Recurrent Endometrial Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
High Grade Fallopian Tube Serous Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Ovarian Carcinosarcoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Cancer
Fallopian Tube Clear Cell Adenocarcinoma

Interventions: Drug: Entinostat
Drug: Olaparib

First Posted Date: 2019-04-23

Last Posted Date: 2022-04-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT03924245

Locations: 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Entinostat
Drug: Enzalutamide

First Posted Date: 2019-02-04

Last Posted Date: 2021-08-02

Lead Sponsor: George Washington University

Target Recruit Count: 6

Registration Number: NCT03829930

Locations: 🇺🇸
George Washington University - Medical Faculty Associates, Washington, District of Columbia, United States

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Entinostat
Drug: Pembrolizumab

First Posted Date: 2018-12-05

Last Posted Date: 2024-01-10

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT03765229

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy